None of the other SLE samples blocked IFNα signaling.<h4>Conclusions</h4>We noted an increased prevalence of pre-existing anti-IFNα autoantibodies in SLE patients with COVID-19 compared to the reported prevalence in lupus patients and the general population with severe COVID-19. The gene discussed is IFNA1; the disease is systemic lupus erythematosus.